引入新技术的启示:金属对金属髋关节置换与当代替代方案在国家关节登记中的比较生存建模
该研究基于英国国家关节登记(NJR)2003年4月至2014年12月数据,比较金属对金属(MoM)髋关节置换与替代方案的翻修率。MoM髋关节表面置换10年翻修率12.6%,预期仅4.8%;有柄MoM全髋置换10年失败率19.8%,预期3.9%。每100例MoM表面置换10年超额翻修7.8例,每100例有柄MoM全髋置换超额翻修15.9例,相当于8,021例超额首次翻修。
要点
- MoM髋关节表面置换10年翻修率12.6%,若用替代方案预期为4.8%。
- 有柄MoM全髋置换10年失败率19.8%,若用替代方案预期为3.9%。
- 每100例MoM表面置换和有柄MoM全髋置换10年分别超额翻修7.8例和15.9例。
核心结论
- 本研究强调广泛且监测不足地采用医疗技术会带来后果,全球已植入超过100万例MoM髋假体,全球范围的超额失败将是巨大的。
- 这种在没有充分支持数据的情况下采用新技术的做法绝不能重演。
研究设计与样本
- 基于人群的纵向队列研究,数据来自2003年4月至2014年12月英格兰、威尔士和北爱尔兰的国家关节登记(NJR)。
- 分别确定有柄MoM全髋置换和髋表面置换的植入物失败率,并使用灵活参数生存模型与使用现有替代方案时预期的失败率进行比较。
- 使用Kaplan-Meier生存分析比较MoM原发置换失败患者与无MoM全髋置换失败患者的累积再翻修率。
主要发现
- 37,555例患者接受MoM髋表面置换,10年翻修率为12.6%(95%CI:12.2%至13.1%),若使用替代植入物预测翻修率为4.8%。
- 32,024例有柄MoM全髋置换10年失败率为19.8%(95%CI:18.9%至20.8%),若使用替代方案预期失败率为3.9%。
- 每100例MoM髋表面置换10年超额翻修7.8例,每100例有柄MoM全髋置换10年超额翻修15.9例,相当于8,021例超额首次翻修。
- 7年再翻修率:有柄无MoM全髋置换为14.9%(95%CI:13.8%至16.2%),MoM髋表面置换为18.0%(95%CI:15.7%至20.7%),有柄MoM全髋置换为19.8%(95%CI:17.0%至23.0%)。
关键数值与推荐
- MoM髋表面置换10年翻修率12.6%(95%CI:12.2%至13.1%)vs 替代植入物预测翻修率4.8%。
- 有柄MoM全髋置换10年失败率19.8%(95%CI:18.9%至20.8%)vs 替代方案预期失败率3.9%。
- 每100例MoM髋表面置换10年超额翻修7.8例,每100例有柄MoM全髋置换10年超额翻修15.9例,相当于8,021例超额首次翻修。
- 7年再翻修率:有柄无MoM全髋置换14.9%(95%CI:13.8%至16.2%),MoM髋表面置换18.0%(95%CI:15.7%至20.7%),有柄MoM全髋置换19.8%(95%CI:17.0%至23.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New medical technologies are often used widely without adequate supporting data, a practice that can lead to widespread catastrophic failure such as occurred with metal-on-metal (MoM) hip replacements. We determined both how revision rates would have differed if, instead of receiving MoM hip replacements, patients had received existing alternatives and the subsequent cumulative re-revision rates of the patients who did receive MoM hip replacements compared with alternatives. METHODS: This study is a population-based longitudinal cohort study of patient data recorded in the National Joint Registry (NJR) for England, Wales and Northern Ireland between April 2003 and December 2014. We ascertained implant failure rates separately among stemmed MoM total hip replacement (THR) and hip-resurfacing procedures and, using flexible parametric survival modeling, compared them with the failure rates that would have been expected had existing alternatives been used. We used Kaplan-Meier survivorship analysis to compare cumulative re-revision of patients who received stemmed MoM primary replacements that failed and of those who underwent hip resurfacing that failed with those whose non-MoM THRs had failed. RESULTS: In all, 37,555 patients underwent MoM hip resurfacing, with a 10-year revision rate of 12.6% (95% confidence interval [CI]: 12.2% to 13.1%) compared with a predicted revision rate of 4.8% if alternative implants had been used. The 32,024 stemmed MoM THRs had a 19.8% (95% CI: 18.9% to 20.8%) 10-year failure rate compared with an expected rate of 3.9% if alternatives had been used. For every 100 MoM hip-resurfacing procedures, there were 7.8 excess revisions by 10 years, and for every 100 stemmed MoM THR procedures, there were 15.9, which equates to 8,021 excess first revisions. Seven-year re-revision rates were 14.9% (95% CI: 13.8% to 16.2%) for stemmed non-MoM THRs, 18.0% (95% CI: 15.7% to 20.7%) for MoM hip resurfacing, and 19.8% (95% CI: 17.0% to 23.0%) for stemmed MoM THRs. CONCLUSIONS: This study highlights the consequences of widespread and poorly monitored adoption of a medical technology. Over 1 million MoM hip prostheses were implanted worldwide. The excess failure on a global scale will be enormous. This practice of adopting new technologies without adequate supporting data must not be repeated. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Hunt LP, Whitehouse MR, Beswick A, et al. Implications of Introducing New Technology: Comparative Survivorship Modeling of Metal-on-Metal Hip Replacements and Contemporary Alternatives in the National Joint Registry. J Bone Joint Surg Am. 2018. PMID: 29406339. doi:10.2106/JBJS.17.00039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。